Spexis AG
Develops therapeutics for rare diseases, oncology, and antimicrobial resistance.
SPEX | SW
Overview
Corporate Details
- ISIN(s):
- CH0106213793
- LEI:
- 391200S8HJE1I96FIG04
- Country:
- Switzerland
- Address:
- Hegenheimermattweg 125, 4123 Allschwil
- Website:
- https://www.polyphor.com/
- Sector:
- Manufacturing
Description
Spexis AG is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for rare diseases and oncology. The company leverages its expertise in macrocycle technology to create novel drug candidates designed to address high unmet medical needs. Its pipeline is advanced through a strategy that includes in-house discovery, development, in-licensing, and the acquisition of promising molecules. The primary therapeutic areas of interest include rare diseases and cancer, with an additional focus on antimicrobial resistance.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-03-09 08:27 |
Strategy Update and 2021 Financial Results
|
English | 14.2 KB | ||
| 2022-03-09 07:25 |
Spexis to present strategy update and full-year 2021 financial results on March…
|
English | 8.5 KB | ||
| 2022-03-03 08:08 |
CARB-X milestone
|
English | 18.4 KB | ||
| 2022-03-03 07:15 |
Spexis achieves first CARB-X milestone for its thanatin derivatives program and…
|
English | 14.5 KB | ||
| 2021-12-30 07:15 |
Polyphor closes merger with EnBiotix and is renamed Spexis
|
English | 10.6 KB | ||
| 2021-12-29 07:30 |
Polyphor to inform about the financing of its merger partner EnBiotix
|
English | 9.6 KB | ||
| 2021-12-15 07:15 |
Polyphor and EnBiotix announce dosing of first patient in a first-in-human clin…
|
English | 10.0 KB | ||
| 2021-10-29 07:15 |
Polyphor shareholders approve all resolutions for the planned merger with EnBio…
|
English | 10.2 KB | ||
| 2021-10-15 07:30 |
Swiss Takeover Board confirms Absence of an Obligation to make a Public Takeove…
|
English | 10.2 KB | ||
| 2021-09-27 07:30 |
Polyphor publishes invitation to Extraordinary General Meeting and announces fi…
|
English | 16.4 KB | ||
| 2021-09-10 07:30 |
Polyphor and EnBiotix announce closing of purchase agreement of Inhaled Murepav…
|
English | 7.7 KB | ||
| 2021-09-01 19:00 |
Polyphor and EnBiotix announce signing of merger agreement and sale of Inhaled …
|
English | 16.1 KB | ||
| 2021-08-03 19:00 |
Polyphor provides final update on the Phase III FORTRESS study of balixafortide…
|
English | 11.0 KB | ||
| 2021-07-30 07:30 |
Polyphor to extend period for its strategic evaluation by up to four weeks
|
English | 7.6 KB | ||
| 2021-07-16 07:30 |
Polyphor provides update on the future of the FORTRESS study of balixafortide a…
|
English | 9.6 KB |
Automate Your Workflow. Get a real-time feed of all Spexis AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Spexis AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Spexis AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-21 | N/A | Executive member | Other | None | N/A |
Peer Companies
